KYMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kymera Therapeutics Inc (KYMR) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has promising clinical developments and analyst optimism, the recent financial performance and cautious market sentiment suggest waiting for further clarity on its growth trajectory.
The technical indicators are mixed. The MACD is positive, indicating bullish momentum, but it is contracting. RSI is neutral at 49.284, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 86.436, with support at 83.432 and resistance at 89.441.
Kymera's KT-621 received FDA Fast Track designation for eosinophilic asthma, which could expedite its market entry. The drug is in Phase 2b trials for two indications, with promising preliminary data. Analysts maintain a positive outlook, with several raising price targets recently.
The stock fell 2.63% despite the FDA designation, reflecting cautious market sentiment. Financial performance in Q4 2025 showed a significant revenue drop (-61.18% YoY) and a net loss, despite slight improvements in EPS and net income. Options data indicates bearish sentiment with a high put-call volume ratio (2.48).
In Q4 2025, revenue dropped significantly (-61.18% YoY) to $2.87M. Net income improved slightly but remains negative at -$86.98M. EPS improved to -0.97 (+10.23% YoY). Gross margin remains at 100%.
Analysts are generally bullish, with multiple firms maintaining Buy or Overweight ratings. Recent price targets range from $100 to $140, reflecting optimism about Kymera's clinical pipeline and market opportunities.
